Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 04/12/17

Research Spotlights

Blinatumomab Extends Survival for Patients with Advanced ALL

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial

NCI-sponsored Trials in Precision Medicine

PET-CT-Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer

TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence
May Forgo Chemotherapy

NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities

Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), announced June 1, 2015, at the annual meeting of the American Society of Clinical Oncology that the precision medicine trial will open to patient enrollment in July. The trial seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of their cancer type. More…

Opportunities in Precision Medicine

On January 30, 2015, President Obama unveiled details about the Precision Medicine Initiative, a bold new research effort to revolutionize how we improve health and treat disease. Precision medicine uses information about the genes, proteins, and other features of a person's cancer to diagnose or treat their particular disease. More…

The Investigational Drug Steering Committee (IDSC)

The Investigational Drug Steering Committee (IDSC) was established following recommendations by the Clinical Trials Working Group (CTWG). The IDSC was created to collaborate with NCI in the design and prioritization of early phase drug development trials with agents for which CTEP holds an IND. IDSC members include the Principal Investigators of CTEPs Experimental Therapeutics Clinical Trail Network (ETCTN), representatives from the each of the Cooperative Groups that comprise the National Clinical Trial Network (NCTN), a patient advocate, and Subject Matter Experts in drug development, radiation oncology, clinical pharmacology, clinical immunology, clinical trial design, omics, biostatistics and imaging. More…

The NCI Experimental Therapeutics Program (NExT)

DCTD and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through a joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program, called the NCI Experimental Therapeutics (NExT) program, combines the strengths of DCTDs extensive expertise in anticancer drug development with CCRs dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center. More…

Operational Efficiency Working Group (OEWG)

CTEP is working with investigators to implement the recommendations of the OEWG presented by Dr. James Doroshow, Director of the NCI Division of Cancer Treatment and Diagnosis, to the NCI Clinical Trials and Translational Research Advisory Committee. The goal of the OEWG recommendations is to shorten the timeline necessary for trial activation. More…